Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34+cell therapy:A clinical trial  

作　　者：Takayasu Ohtake Tsutomu Sato Toshitaka Tsukiyama Suguru Muraoka Ayaka Mitomo Haruka Maruyama Mizuki Yamano Yasuhiro Mochida Kunihiro Ishioka Machiko Oka Hidekazu Moriya Sumi Hidaka Haruchika Masuda Takayuki Asahara Shuzo Kobayashi 

机构地区：[1]Regenerative Medicine,The Center for Cell Therapy&Regenerative Medicine,Shonan Kamakura General Hospital,Kamakura 247-8533,Kanagawa,Japan [2]Kidney Disease and Transplant Center,Shonan Kamakura General Hospital,Kamakura 247-8533,Kanagawa,Japan [3]Regenerative Medicine,Shonan Research Institute of Innovative Medicine,Kamakura 247-8533,Kanagawa,Japan [4]Clinical Laboratory,Shonan Kamakura General Hospital,Kamakura 247-8533,Kanagawa,Japan [5]Department of Radiology and Interventional Radiology,Shonan Kamakura General Hospital,Kamakura 247-8533,Japan

出　　处：《World Journal of Stem Cells》2024年第12期1012-1021,共10页世界干细胞杂志（英文）

摘　　要：BACKGROUND To date,no specific treatment has been established to reverse progressive chronic kidney disease(CKD).AIM To evaluate the safety and efficacy of autologous CD34^(+)cell transplantation in CKD patients who exhibited a progressive decline in renal function.METHODS The estimated glomerular filtration rate(eGFR)at the beginning of the study was 15.0-28.0 mL/minute/1.73 m^(2).After five days of treatment with the granulocyte colony-stimulating factor,mononuclear cells were harvested and CD34^(+)cells were magnetically collected.CD34^(+)cells were directly injected into the bilateral renal arteries twice(at 0 and 3 months),and their safety and efficacy were evaluated for 6 months.RESULTS Four patients were enrolled and completed the study.Three of four patients showed improvement in eGFR slope(eGFR slope>0 mL/minute/1.73 m^(2)),with the monthly slope of eGFR(delta eGFR)changing from-1.36±1.1(pretreatment)to^(+)0.22±0.71(at 6 months)mL/minute/1.73 m^(2)/month(P=0.135)after cell therapy.Additionally,intrarenal resistive index(P=0.004)and shear wave velocity(P=0.04)were significantly improved after cell therapy.One patient experienced transient fever after cell therapy,and experienced bone pain during granulocyte colony-stimulating factor administration.However,no severe adverse events were reported.CONCLUSION In conclusion,our findings suggest that repetitive peripheral blood-derived autologous CD34^(+)cell transplantation into the renal arteries is safe,feasible,and may be effective for patients with progressive CKD.However,a large-scale clinical trial is warranted to validate the efficacy of repetitive regenerative cell therapy using autologous CD34^(+)cells in patients with progressive CKD.

关 键 词：CD34+cell Chronic kidney disease Clinical trial Granulocyte colony-stimulating factor Regenerative therapy 

分 类 号：R692[医药卫生—泌尿科学]